Celldex Therapeutics, Inc. (CLDX) Receives $8.13 Consensus Price Target from Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a consensus rating of “Hold” from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $8.13.

Several research analysts recently weighed in on CLDX shares. WBB Securities reaffirmed a “buy” rating and set a $10.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, December 6th. HC Wainwright reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, November 7th. Finally, BidaskClub raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, January 5th.

Hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC bought a new position in Celldex Therapeutics during the third quarter valued at about $101,000. OxFORD Asset Management LLP acquired a new position in shares of Celldex Therapeutics in the 3rd quarter valued at $122,000. Teacher Retirement System of Texas boosted its position in shares of Celldex Therapeutics by 325.0% in the 4th quarter. Teacher Retirement System of Texas now owns 43,253 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 33,077 shares during the period. Voya Investment Management LLC boosted its position in shares of Celldex Therapeutics by 17.4% in the 2nd quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 7,499 shares during the period. Finally, BlueCrest Capital Management Ltd acquired a new position in shares of Celldex Therapeutics in the 2nd quarter valued at $158,000. 52.14% of the stock is owned by institutional investors and hedge funds.

Shares of Celldex Therapeutics (CLDX) traded down $0.03 during mid-day trading on Friday, reaching $2.29. The company had a trading volume of 1,338,300 shares, compared to its average volume of 1,201,087. Celldex Therapeutics has a fifty-two week low of $2.20 and a fifty-two week high of $3.94. The company has a market capitalization of $312.77, a PE ratio of -2.27 and a beta of 2.57.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/15/celldex-therapeutics-inc-cldx-receives-8-13-consensus-price-target-from-analysts.html.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply